BRKR Logo

Bruker Corp (BRKR) Stock Forecast & Price Prediction

Live BRKR Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Medical Devices

$57.43

+1.04 (1.84%)

12 Month Price Forecast For BRKR

$57.43
Current Price
$8.71B
Market Cap
15 Ratings
Buy 10
Hold 5
Sell 0
Wall St Analyst Ratings

Distance to BRKR Price Forecasts

+48.0%
To High Target of $85.00
+26.1%
To Median Target of $72.41
+4.5%
To Low Target of $60.00

BRKR Price Momentum

+0.8%
1 Week Change
-5.3%
1 Month Change
-22.3%
1 Year Change
-2.0%
Year-to-Date Change
-39.5%
From 52W High of $94.86
+19.5%
From 52W Low of $48.07

๐Ÿค” Considering Bruker (BRKR)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 12:08 PM UTC

BRKR Analyst Ratings & Price Targets

Based on our analysis of 18 Wall Street analysts, BRKR has a consensus that is bullish. The median price target is $72.41, with forecasts ranging from $60.00 to $85.00. Currently, there are 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings.

With BRKR currently trading at $57.43, the median price forecast suggests a 26.1% upside. The most optimistic forecast comes from Puneet Souda at SVB Leerink, projecting a 48.0% upside, while Matthew Sykes at Goldman Sachs provides the most conservative target, suggesting a 4.5% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

BRKR Analyst Consensus

10
Buy
5
Hold
0
Sell

BRKR Price Target Range

Low
$60.00
Average
$72.41
High
$85.00
Current: $57.43

Latest BRKR Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for BRKR.

Date Firm Analyst Rating Change Price Target
Jan 17, 2025 Guggenheim Subbu Nambi Buy Reiterates $0.00
Dec 19, 2024 Guggenheim Subbu Nambi Buy Initiates $72.00
Dec 13, 2024 B of A Securities Derik De Bruin Buy Maintains $80.00
Dec 10, 2024 UBS Dan Leonard Neutral Assumes $66.00
Dec 5, 2024 Goldman Sachs Matthew Sykes Neutral Upgrade $60.00
Nov 6, 2024 TD Cowen Dan Brennan Hold Maintains $70.00
Nov 6, 2024 Citigroup Patrick Donnelly Buy Maintains $75.00
Nov 6, 2024 Barclays Terence Malone Overweight Maintains $69.00
Nov 6, 2024 Wells Fargo Brandon Couillard Overweight Maintains $75.00
Oct 15, 2024 Barclays Terence Malone Overweight Initiates $75.00
Sep 30, 2024 Wolfe Research Doug Schenkel Peer Perform Downgrade $0.00
Aug 27, 2024 Wells Fargo Brandon Couillard Overweight Initiates $78.00
Aug 7, 2024 TD Cowen Max Masucci Hold Maintains $72.00
Jul 11, 2024 Citigroup Buy Maintains $0.00
Jul 10, 2024 Citigroup Patrick Donnelly Buy Maintains $80.00
Jul 9, 2024 Goldman Sachs Matthew Sykes Sell Maintains $60.00
May 20, 2024 Stifel Daniel Arias Hold Maintains $77.00
May 20, 2024 B of A Securities Derik De Bruin Buy Maintains $90.00
Apr 10, 2024 Goldman Sachs Matthew Sykes Sell Maintains $74.00
Mar 1, 2024 UBS John Sourbeer Buy Maintains $102.00

Stocks Similar to Bruker Corp

The following stocks are similar to Bruker based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Bruker Corp (BRKR) Financial Data

Bruker Corp has a market capitalization of $8.71B with a P/E ratio of 27.7x. The company generates $3.24B in trailing twelve-month revenue with a 9.4% profit margin.

Revenue growth is +16.4% quarter-over-quarter, while maintaining an operating margin of +10.0% and return on equity of +19.7%.

Valuation Metrics

Market Cap $8.71B
Enterprise Value $11.03B
P/E Ratio 27.7x
PEG Ratio 21.2x
Price/Sales 2.7x

Growth & Margins

Revenue Growth (YoY) +16.4%
Gross Margin +48.4%
Operating Margin +10.0%
Net Margin +9.4%
EPS Growth -53.6%

Financial Health

Cash/Price Ratio +1.8%
Current Ratio 1.7x
Debt/Equity 132.6x
ROE +19.7%
ROA +4.8%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Bruker Corp logo

Bruker Corp (BRKR) Company Overview

About Bruker Corp

What They Do

Develops scientific instruments and analytical solutions.

Business Model

The company generates revenue by developing, manufacturing, and distributing a wide range of scientific instruments and diagnostic solutions across various segments including life sciences, analytical tools, and superconducting technologies. It serves diverse markets including healthcare, research, and industrial applications, with products that address specific needs like pathogen identification and molecular diagnostics.

Additional Information

Bruker Corporation operates through four main segments and offers a variety of specialized tools and systems, including mass spectrometry and portable analytical instruments. The company was established in 1991 and is based in Billerica, Massachusetts, positioning itself as a key player in the scientific instruments market with a strong international presence.

Company Information

Sector

Healthcare

Industry

Medical Devices

Employees

9,707

CEO

Dr. Frank H. Laukien Ph.D.

Country

United States

IPO Year

2000

Bruker Corp (BRKR) Latest News & Analysis

BRKR stock latest news image
Quick Summary

BRKR's NANO Life Science fluorescence microscopy is benefitting from increased product innovation and growing demand for research applications.

Why It Matters

BRKR's growth in fluorescence microscopy indicates strong market demand and innovation, potentially leading to increased revenue and competitive advantage, impacting stock performance positively.

Source: Zacks Investment Research
Market Sentiment: Positive
BRKR stock latest news image
Quick Summary

Bruker Corporation (NASDAQ: BRKR) is currently undervalued at under $74, with growth potential from strategic acquisitions in high-growth markets, despite weaker EPS and margins.

Why It Matters

Bruker Corporation's undervaluation and strategic acquisitions position it for significant growth in high-demand markets, potentially enhancing profitability and appealing to investors seeking upside.

Source: Seeking Alpha
Market Sentiment: Positive
BRKR stock latest news image
Quick Summary

Bruker has launched the LUMOS II ILIM QCL-based IR microscope, targeting the pharmaceutical and life sciences research sectors.

Why It Matters

Bruker's launch of the LUMOS II ILIM QCL-based IR microscope enhances its product offerings, potentially driving revenue growth in the pharma and life sciences sectors, impacting stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
BRKR stock latest news image
Quick Summary

Bruker Corporation (Nasdaq: BRKR) launched the LUMOSโ„ข II ILIM, a new infrared imaging microscope enhancing imaging speed and resolution for pharma and life science research.

Why It Matters

Bruker's launch of the LUMOS II ILIM could boost revenue from pharma and life sciences, enhancing market position and driving stock performance, appealing to growth-focused investors.

Source: Business Wire
Market Sentiment: Neutral
BRKR stock latest news image
Quick Summary

Bruker Corporation (Nasdaq: BRKR) will present at the J.P. Morgan Healthcare Conference on January 13, 2025, at 3:45 PM PST, featuring key executives. A live audio webcast will be available.

Why It Matters

Bruker's participation in a major healthcare conference signals potential growth opportunities and strategic initiatives, influencing investor sentiment and stock performance.

Source: Business Wire
Market Sentiment: Neutral
BRKR stock latest news image
Quick Summary

Bruker Corporation announced that a U.S. District Court upheld a jury's damages award in a patent infringement case involving its NanoString business and 10x Genomics.

Why It Matters

The court's ruling on damages for Bruker's NanoString products affects financial outlook and potential liabilities, impacting stock performance and investor confidence.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About BRKR Stock

What is Bruker Corp's (BRKR) stock forecast for 2025?

Based on our analysis of 18 Wall Street analysts, Bruker Corp (BRKR) has a median price target of $72.41. The highest price target is $85.00 and the lowest is $60.00.

Is BRKR stock a good investment in 2025?

According to current analyst ratings, BRKR has 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $57.43. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for BRKR stock?

Wall Street analysts predict BRKR stock could reach $72.41 in the next 12 months. This represents a 26.1% increase from the current price of $57.43. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Bruker Corp's business model?

The company generates revenue by developing, manufacturing, and distributing a wide range of scientific instruments and diagnostic solutions across various segments including life sciences, analytical tools, and superconducting technologies. It serves diverse markets including healthcare, research, and industrial applications, with products that address specific needs like pathogen identification and molecular diagnostics.

What is the highest forecasted price for BRKR Bruker Corp?

The highest price target for BRKR is $85.00 from Puneet Souda at SVB Leerink, which represents a 48.0% increase from the current price of $57.43.

What is the lowest forecasted price for BRKR Bruker Corp?

The lowest price target for BRKR is $60.00 from Matthew Sykes at Goldman Sachs, which represents a 4.5% increase from the current price of $57.43.

What is the overall BRKR consensus from analysts for Bruker Corp?

The overall analyst consensus for BRKR is bullish. Out of 18 Wall Street analysts, 10 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $72.41.

How accurate are BRKR stock price projections?

Stock price projections, including those for Bruker Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.